Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.

Publication ,  Journal Article
Bernacki, SH; Stankovic, AK; Williams, LO; Beck, JC; Herndon, JE; Snow-Bailey, K; Prior, TW; Matteson, KJ; Wasserman, LM; Cole, EC; Stenzel, TT
Published in: J Mol Diagn
November 2003

Positive control materials for clinical molecular genetic testing applications are currently in critically short supply or non-existent for many genetically based diseases of public health importance. Here we demonstrate that anonymous, residual, clinical blood samples are potential sources of viable lymphocytes for establishing Epstein-Barr virus (EBV)-transformed blood lymphocyte cell lines. We attempted to transform 34 residual blood samples, and analyzed transformation success with respect to sample age, anticoagulant, storage temperature, volume, hemolysis, and patient age and sex. In univariate analysis, sample age was significantly associated with transformation success (P = 0.002). The success rate was 67% (6 of 9) for samples 1 to 7 days old, 38% (3 of 8) for samples 8 to 14 days old and 0% for samples 15 to 21 (0 of 11) days old. When we controlled for sample age in multivariate logistic regression, anticoagulant and storage temperature approached significance (P = 0.070 and 0.087, respectively; samples in acid citrate dextrose (ACD) and refrigerated samples were more likely to transform). Based on these findings, we suggest that samples collected in either ACD or ethylene diamine tetraacetic acid, and up to 14 days old (refrigerated) or 7 days old (stored ambient), are reasonable candidates for EBV transformation. The transformation rate for samples that met these criteria was 63% (10 of 16). Implementation of this process could help alleviate the shortage of positive control materials for clinical molecular genetic testing.

Duke Scholars

Published In

J Mol Diagn

DOI

ISSN

1525-1578

Publication Date

November 2003

Volume

5

Issue

4

Start / End Page

227 / 230

Location

United States

Related Subject Headings

  • Time Factors
  • Temperature
  • Sex Characteristics
  • Quality Control
  • Pathology
  • Molecular Biology
  • Middle Aged
  • Male
  • Lymphocytes
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bernacki, S. H., Stankovic, A. K., Williams, L. O., Beck, J. C., Herndon, J. E., Snow-Bailey, K., … Stenzel, T. T. (2003). Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing. J Mol Diagn, 5(4), 227–230. https://doi.org/10.1016/S1525-1578(10)60478-3
Bernacki, Susan H., Ana K. Stankovic, Laurina O. Williams, Jeanne C. Beck, James E. Herndon, Karen Snow-Bailey, Thomas W. Prior, et al. “Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.J Mol Diagn 5, no. 4 (November 2003): 227–30. https://doi.org/10.1016/S1525-1578(10)60478-3.
Bernacki SH, Stankovic AK, Williams LO, Beck JC, Herndon JE, Snow-Bailey K, et al. Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing. J Mol Diagn. 2003 Nov;5(4):227–30.
Bernacki, Susan H., et al. “Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.J Mol Diagn, vol. 5, no. 4, Nov. 2003, pp. 227–30. Pubmed, doi:10.1016/S1525-1578(10)60478-3.
Bernacki SH, Stankovic AK, Williams LO, Beck JC, Herndon JE, Snow-Bailey K, Prior TW, Matteson KJ, Wasserman LM, Cole EC, Stenzel TT. Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing. J Mol Diagn. 2003 Nov;5(4):227–230.
Journal cover image

Published In

J Mol Diagn

DOI

ISSN

1525-1578

Publication Date

November 2003

Volume

5

Issue

4

Start / End Page

227 / 230

Location

United States

Related Subject Headings

  • Time Factors
  • Temperature
  • Sex Characteristics
  • Quality Control
  • Pathology
  • Molecular Biology
  • Middle Aged
  • Male
  • Lymphocytes
  • Humans